GR20080100530A - 1-4 βενζοξαζινικα αναλογα - Google Patents
1-4 βενζοξαζινικα αναλογαInfo
- Publication number
- GR20080100530A GR20080100530A GR20080100530A GR20080100530A GR20080100530A GR 20080100530 A GR20080100530 A GR 20080100530A GR 20080100530 A GR20080100530 A GR 20080100530A GR 20080100530 A GR20080100530 A GR 20080100530A GR 20080100530 A GR20080100530 A GR 20080100530A
- Authority
- GR
- Greece
- Prior art keywords
- subject
- pharmaceutically acceptable
- compound
- administering
- ester
- Prior art date
Links
- PVTXJGJDOHYFOX-UHFFFAOYSA-N 2h-1,4-benzoxazine Chemical class C1=CC=C2N=CCOC2=C1 PVTXJGJDOHYFOX-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 229940079593 drug Drugs 0.000 abstract 3
- 239000003814 drug Substances 0.000 abstract 3
- 150000002148 esters Chemical class 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- 208000029028 brain injury Diseases 0.000 abstract 2
- -1 but not limited to Chemical class 0.000 abstract 2
- 230000004770 neurodegeneration Effects 0.000 abstract 2
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 2
- 238000011282 treatment Methods 0.000 abstract 2
- 206010012289 Dementia Diseases 0.000 abstract 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 abstract 1
- 241000223997 Toxoplasma gondii Species 0.000 abstract 1
- 208000030886 Traumatic Brain injury Diseases 0.000 abstract 1
- 230000030833 cell death Effects 0.000 abstract 1
- 230000007850 degeneration Effects 0.000 abstract 1
- 239000003257 excitatory amino acid Substances 0.000 abstract 1
- 230000002461 excitatory amino acid Effects 0.000 abstract 1
- 231100000318 excitotoxic Toxicity 0.000 abstract 1
- 230000003492 excitotoxic effect Effects 0.000 abstract 1
- 229930195712 glutamate Natural products 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 206010027175 memory impairment Diseases 0.000 abstract 1
- 230000002503 metabolic effect Effects 0.000 abstract 1
- 230000004112 neuroprotection Effects 0.000 abstract 1
- 230000002887 neurotoxic effect Effects 0.000 abstract 1
- 244000045947 parasite Species 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 208000020431 spinal cord injury Diseases 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 239000003053 toxin Substances 0.000 abstract 1
- 231100000765 toxin Toxicity 0.000 abstract 1
- 108700012359 toxins Proteins 0.000 abstract 1
- 230000009529 traumatic brain injury Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
- C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Η παρούσα εφεύρεση περιλαμβάνει τουλάχιστον μια ένωση του τύπου I. ΧΗΜΙΚΟΣ ΤΥΠΟΣ(I) όπου: R1, R2, R3, R4, R5, R6, R7, R8 προσδιορίζονται στην περιγραφή ή φαρμακευτικά αποδεκτού εστέρα αυτής, ή άλατος αυτής ή άλατος αυτής το οποίον προκύπτει, από τη προσθήκη οξέος Επίσης, η παρούσα εφεύρεση περιλαμβάνει σκευάσματα, τα οποία περιέχουν τουλάχιστον μια ένωση του τύπου I ή φαρμακευτικά αποδεκτού εστέρα αυτής, ή άλατος αυτής ή άλατος αυτής το οποίον προκύπτει από τη προσθήκη οξέος ως δραστική ουσία σε συνδυασμό με φαρμακευτικά αποδεκτό φορέα, διαλύτη ή έκδοχο. Επίσης, η παρούσα εφεύρεση αφορά σε μέθοδο για την θεραπεία ή προφύλαξη από παθολογίες που σχετίζονται με τις ελεύθερες ρίζες, οι οποίες περιλαμβάνουν, μη δεσμευτικά, αρτηριοσκλήρυνση, γλαύκωμα, καταρράκτη, ραγοειδίτιδα, ινοπλασία (όπισθεν φακού) προώρων, εκφύλιση ωχράς κηλίδας, διάφορες παθήσεις του αμφιβληστροειδούς, χρονία πνευμονοπάθεια, διαβήτη, και ασθένειες του νευρικού συστήματος, όπως η νόσος του Alzheimer, αμυοτροφική πλάγιασκλήρυνση, σκλήρυνση κατά πλάκας και άλλες συσχετιζόμενες με απομυελινοποίηση ασθένειες, διαβητική πολυνευροπάθεια, σύνδρομο Down, νευροπάθεια σχετιζόμενη με HIV, νόσος του Huntington, πολλαπλή συστημική ατροφία, νόσος του Parkinson.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GR20080100530A GR1007084B (el) | 2008-08-07 | 2008-08-07 | 1,4- βενζοξαζινικα αναλογα |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GR20080100530A GR1007084B (el) | 2008-08-07 | 2008-08-07 | 1,4- βενζοξαζινικα αναλογα |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| GR20080100530A true GR20080100530A (el) | 2010-03-31 |
| GR1007084B GR1007084B (el) | 2010-11-26 |
Family
ID=40637180
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GR20080100530A GR1007084B (el) | 2008-08-07 | 2008-08-07 | 1,4- βενζοξαζινικα αναλογα |
Country Status (1)
| Country | Link |
|---|---|
| GR (1) | GR1007084B (el) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1013572A (en) * | 1960-12-01 | 1965-12-15 | Geigy Ag J R | Antimicrobial agents |
| WO1995018114A1 (fr) * | 1993-12-29 | 1995-07-06 | Laboratoires Pharmascience | Derives de la benzoxazine, leurs procedes d'obtention et leur utilisation en tant que medicaments |
| US5786367A (en) * | 1994-07-14 | 1998-07-28 | Otsuka Pharmaceutical Co., Ltd. | Cyclic amide derivatives |
-
2008
- 2008-08-07 GR GR20080100530A patent/GR1007084B/el not_active IP Right Cessation
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1013572A (en) * | 1960-12-01 | 1965-12-15 | Geigy Ag J R | Antimicrobial agents |
| WO1995018114A1 (fr) * | 1993-12-29 | 1995-07-06 | Laboratoires Pharmascience | Derives de la benzoxazine, leurs procedes d'obtention et leur utilisation en tant que medicaments |
| US5786367A (en) * | 1994-07-14 | 1998-07-28 | Otsuka Pharmaceutical Co., Ltd. | Cyclic amide derivatives |
Non-Patent Citations (2)
| Title |
|---|
| "TimTec Stock Library", 20 November 2007, TIMTEC, INC. HARMONY BUSINESS PARK 301-A, NEWARK, DE, 19711, USA * |
| DATABASE CHEMCATS Chemical Abstract Service, Columbus, Ohio, US; 20 November 2007 (2007-11-20), XP002533303, retrieved from STN * |
Also Published As
| Publication number | Publication date |
|---|---|
| GR1007084B (el) | 2010-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20084703L (no) | Triazolopyrazinforbindelser nyttige for behandling av degenerative og inflammatoriske sykdommer | |
| TN2015000368A1 (en) | Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor | |
| TW200637614A (en) | Bendamustine pharmaceutical compositions | |
| BR112013014184A2 (pt) | compostos de triazina [1,2,4] triazolo [4,3-b][1,2,4], método de preparo e seu uso | |
| AU2013270326B2 (en) | Pyrrolo[2,1-f][1,2,4]triazine compound, and preparation method and application thereof | |
| MY170189A (en) | 6-cycloalkyl-1, 5-dihydro-pyrazolo[3,4-d] pyrimidin-4-one derivatives and their use as pde9a inhibitors | |
| CA2918938C (en) | Substituted aminopyrimidine compounds and methods of use | |
| EP4480543A3 (en) | Chiral diaryl macrocycle and use thereof in the treatment of cancer | |
| TW201613593A (en) | Molecules for administration to ROS1 mutant cancer cells | |
| CL2009000695A1 (es) | Compuestos derivados de 6-fenil-imidazo[1,2-a]piridina sustituidos; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; utiles para el tratamiento y prevencion de enfermedades neurodegenerativas, psiquiatricas, inflamatorias, de traumatismos cerebrales y de la epilepsia, entre otras. | |
| EA201270824A1 (ru) | Соединения для уменьшения продукции бета-амилоида | |
| HK1201065A1 (en) | Novel quinoxaline inhibitors of pi3k | |
| AU2012243329A8 (en) | 5-substituted iminothiazines and their mono-and dioxides as BACE inhibitors,compositions,and their use | |
| WO2012075492A3 (en) | Carbocycle-substituted purine and 7-deazapurine compounds | |
| WO2012047017A3 (ko) | 2,3-디히드로-이소인돌-1-온 유도체 및 이를 포함하는 조성물 | |
| WO2017009843A3 (en) | Compositions, articles of manufacture and methods for treating cancer | |
| MY138708A (en) | Biaryloxymethylarenecarboxylic acids | |
| UA101393C2 (ru) | КОМПОЗИЦИИ И ПРИМЕНЕНИЕ ПРОИЗВОДНЫХ ТРИАЗОЛА ДЛЯ ЛЕЧЕНИЯ β-АМИЛОИДОЗОВ И СИНУКЛЕИНОПАТИЙ | |
| WO2011107812A3 (en) | Stabilized pharmaceutical composition | |
| EP2215054B8 (en) | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | |
| WO2015107536A3 (en) | Fixed dose combination comprising linagliptin and metformin hci | |
| UA94036C2 (ru) | Фармацевтическая композиция бендамустина, предназначенная для лиофилизации | |
| GR20080100530A (el) | 1-4 βενζοξαζινικα αναλογα | |
| WO2008036733A3 (en) | Methods for treatment of vesicle transport disorders | |
| IN2014CN04009A (el) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PG | Patent granted | ||
| ML | Lapse due to non-payment of fees |
Effective date: 20150304 |